Beta-blockers/calcium channel blockers

amlodipine

norvasc

antihypertensive

therapeutic class of amlodipine/norvasc

Dihydropyridine calcium channel blocker (DHP CCB)

pharmacologic class of amlodipine/norvasc

felodipine

plendil

antihypertensive

therapeutic class of felodipine/plendil

DHP CCB

Pharmacologic class of feoldipine/plendil

nifedipine

procardia

antihypertensive

therapeutic class of nifedipine/procardia

DHP CCB

pharmacologic class of nifedipine/procardia

diltiazem

cardizem

rate control

therapeutic class of diltiazem/cardizem

non-dihydropyridine calcium channel blocker (NON-DHP CCB)

pharmacologic class of diltazem/cardizem

verapamil

verelan

rate control

therapeutic class of verapamil/verelan

NON-DHP CCB

pharmacologic class of verapamil/verelan

atenolol

tenormin

antihypertensive

therapeutic class of -lol

beta blocker

pharmacologic class of -lol drugs

bisoprolol

zabeta

carvedilol

coreg

labetalol

trandate

metoprolol tartrate

lopressor

metoprolol succinate

toprol

nebivolol

bystolic

propranolol

inderal

blocks noradrenergic receptors

MOA of beta blocker

blocks calcium channels in peripheral smooth muscles

MOA for DHP-CCBs

blocks calcium channels in the heart

MOA for NON-DHP CCBs

bradycardia

major characteristics of beta blockers

peripheral edema

major characteristics for DHP CCBs

bradycardia

major characteristic of NON-DHP CCBs